Nov 8, 2024
Dr. Nunes' initial project report.
Nov 6, 2024
Initial progress report.
Nov 2, 2024
The mid-year progress report for Dr. Stephen Tapscott’s project.
Jul 11, 2024
Patient study update by Dr. Kyba after a Covid hiatus.
Jun 27, 2024
Findings indicate selective interactions of RNA binding proteins with HSATII RNA, which may impact mRNA processing pathways
downstream of DUX4 expression; and that HSATII RNA structure dictates protein recruitment.
Jun 20, 2024
FSHD Straight Talk: 2024 World FSHD Special!
May 18, 2024
The progress report highlights advancements in constructing an MRI data-lake for studying Facioscapulohumeral Muscular Dystrophy (FSHD) using AI segmentation techniques.
May 18, 2024
Finalizing biopsy fiducial details to ensure correspondence between histology, DUX4, and MRI data, with atlas generation to begin in earnest in the summer of 2024.
May 16, 2024
Developing a comprehensive understanding of DUX4 gene regulation.
Apr 23, 2024
Understanding how FSHD cells differ in autophagy and mitophagy will allow one to identify the key mechanisms involved in this metabolic dysregulation of the disease and identify potential therapeutics. Dr. Heher provides a 6-month update on his work so far.
Mar 17, 2024
Dr. Bugiardini provides the first update to comprehensively understanding global genetic diversity in FSHD.
Feb 17, 2024
An update on the MOVE FSHD study.
Feb 17, 2024
Dr. Heher's final report on very interesting data regarding oxidative stress.
Feb 1, 2024
Dr. Chamberlain is honored by the MDA with the 2024 Legacy Award for Achievement in Research.
Jan 30, 2024
Dr. Arends provides an update to current work.
Oct 10, 2023
Latest update from the MOVE grant.
Sep 19, 2023
We have developed a computational cellular model of FSHD, based on a mechanism where expression of DUX4 (currently the main target for FSHD therapy) leads to muscle cell death.
Jul 5, 2023
Initial progress update.
Connect with us on social media